구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IMiD treatment |
Overview Company | Sung-Soo Park |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which |
MoA Biomarker | biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (27 |
Clinical Safety signal | thrombocytopenia (27 |
Clinical Selected reported efficacy | ORR 48.3% |
Clinical Reported ORR | 48.3% |
Clinical Result source | ClinicalTrials.gov NCT01497496 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01497496 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IMiD treatment |
Overview Company | Sung-Soo Park |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which |
MoA Biomarker | biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (27 |
Clinical Safety signal | thrombocytopenia (27 |
Clinical Selected reported efficacy | ORR 48.3% |
Clinical Reported ORR | 48.3% |
Clinical Result source | ClinicalTrials.gov NCT01497496 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01497496 |
추천 비교
추천 비교